Second, comprehensive pan-pathway immune landscape investigations identified MAPK-mutant tumors as the only “CD8+ T-cell–inflamed” tumors with inherently immunoreactive tumor microenvironments with constitutive cytolysis, subsequently validated in immunocompetent HNSCC models. This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.